Search

A 58-year-old man with refractory multiple myeloma developed oesophageal stricture secondary to mucositis during bone marrow conditioning regimen with melphalan. He had a history of multiple treatments for his condition, including CAR-T-Cell therapy. After receiving high-dose melphalan, he experienced difficulty swallowing solid food and developed mucositis. Despite management, his dysphagia worsened, and he was diagnosed with oesophageal stricture. He underwent oesophageal dilation and other treatments, resulting in significant improvement and resolution of the stricture. [Extracted from the article]

This article describes two cases of eosinophilic granulomatosis with polyangiitis (EGPA) that developed in patients being treated with montelukast for asthma. The first case involves a 21-year-old man who experienced muscle weakness, skin lesions, dark urine, and other symptoms. The second case involves a 44-year-old woman who experienced muscle aches, joint pains, weight loss, and fatigue. Both patients were diagnosed with EGPA and treated with prednisone, with symptoms improving after discontinuing montelukast. The article suggests a possible association between montelukast and EGPA. [Extracted from the article]

A retrospective study conducted by the Croatian Cooperative Group for Hematologic diseases described three elderly patients with high-risk aggressive diffuse large B-cell lymphoma who experienced adverse outcomes during treatment with cyclophosphamide, doxorubicin, etoposide, prednisone, rituximab, and vincristine. One patient developed a secondary neoplasm, another experienced disease progression after the first cycle, and the third patient died as a result of the treatment. The study highlights potential risks and lack of efficacy associated with this chemotherapy regimen. [Extracted from the article]

A single-center study conducted between 2015 and 2022 described 17 patients with various hematological disorders who developed drug hypersensitivity reactions (DHR) during treatment with rituximab or off-label obinutuzumab. The patients, aged between 38-81 years, had conditions such as thrombotic thrombocytopenia purpura, lymphoma, and Epstein-Barr virus reactivation. After receiving rituximab therapy, all 17 patients experienced grade 3 or 4 DHRs. Rituximab therapy was discontinued in most cases, and some patients received desensitization before switching to off-label obinutuzumab treatment. However, some patients also developed grade 3+ DHRs secondary to obinutuzumab, leading to discontinuation of the therapy for one patient. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective, non-interventional, real-life study of 23 patients, treated from July 2017 until December 2019, 2 patients [ I ages and sexes not stated i ] were described, who developed febrile neutropenia or haematological toxicity during treatment with polatuzumab vedotin, which was received via a compassionate-use program (in Croatia) along with bendamustine and anti-CD20 monoclonal antibody for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) [ I not all dosages, routes and durations of treatments to reactions onsets stated; outcomes not stated i ]. The patients, who had R/R DLBCL, started receiving treatment with IV polatuzumab vedotin 1.8 mg/kg/cycle via a compassionate-use program along with bendamustin and anti-CD20 monoclonal antibody for a total of up to 6 cycles. Subsequently, the patients developed febrile neutropenia (1 patient) and haematological toxicity (1 patient) secondary to the polatuzumab vedotin, bendamustine and anti-CD20 monoclonal antibody therapy. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study of 9 patients, who underwent irradiation for unresectable or inoperable gastric cancer with bleeding between October 2015 and September 2018, a 78-year-old man developed nausea during treatment with capecitabine and trastuzumab and another 78-year-old man developed platelets, WBC/neutrophil count decrease and nausea during treatment with fluorouracil, folinic acid and oxaliplatin [ I routes, dosages and durations of treatments to reactions onsets not stated i ]. Case 2: This report describes a 78-year-old man, who developed nausea, platelet count decreased and WBC/neutrophil count decreased during treatment with fluorouracil, folinic acid and oxaliplatin. However, he developed haematological toxicity in the form of grade 2 platelet count decrease and grade 4 WBC/neutrophil count decrease. [Extracted from the article]

A 72-year-old woman developed neutropenia and had poor haematologic tolerance during treatment with carboplatin and paclitaxel for ovarian serous carcinoma and peritoneal carcinomatosis. Additionally, she developed asthenia and increased bone pain during treatment with letrozole [doses, routes, durations of treatments to reactions onsets and outcomes not stated]. The woman, who was diagnosed with ovarian serous carcinoma and non-resectable stage IIIC peritoneal carcinomatosis, started receiving treatment with carboplatin and paclitaxel weekly in July 2009 due to low Eastern Cooperative Oncology Group (ECOG) score. [Extracted from the article]

CT scan revealed a massive space occupying lesion (SOL) in the bilateral iliopsoas, indicating the possibility of iliopsoas haematoma or abscess. The rhabdomyolysis with AKI was suspected to have developed secondary to bilateral iliopsoas haematoma or bilateral iliopsoas abscess. [Extracted from the article]

The article presents a case study of a 57-year-old woman who developed haematologic side effects during treatment with ribavirin for chronic hepatitis-E virus infection.

The article presents a case study of a 34-year-old female suffering from bicytopenia after administration with paroxetine.

The article presents case report of a middle-aged woman who developed fatal hypermagnesaemia during treatment with magnesium citrate and magnesium oxide. The woman had a history of chronic constipation and chronic obstructive pulmonary disease. The woman was anuric and was treated with vasopressin, norepinephrine, epinephrine.

The article presents a case study of a 15-year-old female patient who during treatment with the drug phenazopyridine developed complications like skin discolouration, methaemoglobinaemia and acute interstitial nephritis.

The article reports on the study of 5 men and 2 women, aged between 34–64 years who had developed phaeohyphomycosis during treatment with tacrolimus and ciclosporin, mycophenolate mofetil and prednisone or azathioprine. It is also mentioned that a 57-year-old man developed hyponatraemia during the concomitant use of voriconazole and tacrolimus and developed headache, anorexia and weight loss after the concomitant use of itraconazole and tacrolimus.

The article focuses on the development of blood related problems in newborns as a side effect to natalizumab (Tysabri) given to the mothers as per Health Canada.

The article presents the case studies of a 73-year-old man developed with methaemoglobinaemia and 26-year-old man developed with haemolysis while being treated with the use of rasburicase drug.

The article describes the case of four women who developed human cytomegalovirus (HCMV)-related haemophagocytic lymphohistiocytosis (HLH) during treatment with azathioprine for Crohn's disease.

The article describes the clinical cases of two women with refractory Behçcet's disease who developed blood dyscrasias while under high-dose cyclophosphamide treatment regimen.

The article describes the case of an 80-year-old man who developed pancytopenia while taking calcium dobesilate for chronic venous insufficiency.

The article describes the case of an 82-year-old woman who developed fatal pancytopenia while taking clopidogrel for acute coronary syndrome.

The article presents a retrospective cohort study of 34 patients, seven patients aged 2-20 years who were treated with heparin and developed bleeding complications including hemothorax and hematoma of the right transplanted liver.

The article presents a case report of a 60-year-old man who acquired a ribavirin resistance in hepatitis E virus (HEV) infection and developed a haematologic toxicity, after taking ribavirin drug as treatment for his chronic lymphatic leukemia.

The article presents the case of a 77-year-old man undergoing dialysis who developed pancytopenia while receiving carboplatin and etoposide.

The article describes the clinical cases of four patients who developed haematological disorders while under erlotinib treatment regimen for non-small cell lung cancer.

The article describes the case of a girl who developed pancytopenia while receiving treatment with azathioprine for inflammatory bowel disease.

An abstract of the article "A Case of Severe Hematological Toxicity in Response to Pazopanib" by T. Sano and others is presented.

The article describes three cases of myelosuppression induced by azathioprine therapy. One of the patients received azathioprine for the treatment of disseminated prurigo, the other patient received the drug for bullous pemphigoid while the other patient used the drug for atopic dermatitis. It describes the symptoms experienced by the patient consistent with myelosuppression.

The article presents case studies of two boys who developed severe parvovirus B19 (PVB19) infection-related anaemia during immunosuppressive therapy. A six-year-old boy underwent renal transplantation in September 2006, while a 15-year-old boy underwent the same operation in October 2006. Both boys received induction therapy with basiliximab and methylprednisolone, followed by maintenance immunosuppression with prednisone, mycophenolate mofetil (MMF) and tacrolimus.

The article describes the case of five patients who acquired heparin-induced thrombocytopenia (HIT). The patients developed the condition while undergoing treatment with unfractionated or low molecular weight heparins. Two patients have polycythaemia vera while the remaining three are suffering from essential thrombocytosis.

The article describes the case of a 34-year-old man who developed profound thrombocytopenia within 4 hours of treatment with eptifibatide following percutaneous coronary intervention (PCI). Medical history and clinical procedures conducted to the patients are mentioned. The patient's platelet count gradually recovered without the need for platelet transfusion, after his eptifibatide treatment was immediately discontinued.

The article describes three case reports showing the development of neurological disorders, anaemia and thrombocytosis while being treated with phenytoin. One patient, a 59-year-old man, had dysarthria, mild gait ataxia and mystagmus. Another was a 72-year-old man who had right-sided dysdiadochokinesia, past-pointing, bilateral horizontal nystagmus and a marked ataxic gait all associated to cereborvascular disease. A third patient, a 50-year-old man, was hospitalised due to a generalised seizure.

The article describes the case of a 76-year-old man who died after developing pancytopenia while receiving low-dose methotrexate for bullous pemphigoid. He received 2.5 milligrams of oral methotrexate twice weekly. His concomitant medications were calcium folinate, clopidogrel, omeprazole, gabapentin and buflomedil. The patient also developed pneumonia associated with Pseudomonas Aeruginosa septicaemia.

Presents a case report about the development of hyperkalemia and heart arrest in a 77-year-old nondiabetic woman with community-acquired pneumonia who received glucose for glycaemic control. Status of the blood glucose of the patient during and after receiving insulin; Conduction of an external cardiac massage; Role of acute hyperkalemia in the occurrence of cardiac standstill.

Presents a case report on agranulocytosis leading to septicemia and Guillain-Barre syndrome in a 53-year-old woman. Development of the disease during treatment with clozapine for refractory schizophrenia; Increase in the dosage of the drug within 3 months; Findings of the computed tomography scan.